Just days after eking out an FDA expert panel vote in favor of its inhaled antipsychotic Adasuve, Alexza Pharma ($ALXA) has brought in Lazard to investigate the possible sale of assets as it prepares to drop the budget axe on an uncertain number of emp…
Archive for the ‘Adasuve’ Category
Alexza readies "significant" layoffs, brings in Lazard to review asset sale
December 19th, 2011 
John Carroll 
Posted in Adasuve, Alexza Pharmaceuticals, Blog, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos 
Tags: biotech food social media 
Comments OffAlexza shares spike after antipsychotic wins weak embrace from FDA panel
December 13th, 2011 John Carroll Alexza Pharma ($ALXA) just barely managed to clear one of the big hurdles that threatened to once again block its marathon effort at winning an FDA approval of the inhaled antipsychotic treatment Adasuve (formerly AZ-004). An expert FDA committee voted…
Posted in Adasuve, Alexza Pharmaceuticals, Bipolar disorder, Blog, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, Pharmaceuticals, schizophrenia, Startups, Universities, Videos Tags: biotech food social media Comments OffAlexza Pharma shares tank on FDA’s safety concerns about Adasuve
December 9th, 2011 Ryan McBride Investors appeared to get worried after FDA staffers cited worries about lung safety issues with Alexza Pharmaceuticals’ ($ALXA) inhaled anti-agitation drug Adasuve. Shares of the developers stock were down 47.47% yesterday, with the safety concerns po…
Posted in Adasuve, Alexza Pharmaceuticals, Blog, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, Pharmaceuticals, schizophrenia, Startups, Universities, Videos Tags: biotech food social media Comments Off